Literature DB >> 10603130

Body growth of children with steroid-resistant nephrotic syndrome.

K Schärer1, H C Essigmann, F Schaefer.   

Abstract

Whilst it is assumed that body growth is retarded in children with steroid-resistant nephrotic syndrome (NS), the degree of growth failure and the pathomechanisms involved are poorly understood. We collected serial growth data in 45 children (24 males) with steroid-resistant NS usually from onset to end-stage renal disease (ESRD) during childhood (n=10) or until final height was attained (n=27). Mean follow-up time was 9 (2-19) years. Mean initial standardized height was -0.3+/-1.2 standard deviation scores (SDS). Mean final height was +0.4 SDS in males and -1.0 SDS in females (sex difference not significant). In 16 patients with serum creatinine levels consistently <1.2 mg/dl, mean final height SDS was 0.3 SDS higher than that obtained within 6 months of onset. In contrast, 9 children who entered ESRD lost an average of 1.3 SDS from the initial record to ESRD (P=0.017). In prepubertal patients without renal insufficiency, mean height SDS decreased during corticosteroid treatment by 0.3 SDS, followed by a partial catch-up after discontinuation of treatment; the change from initial to final height SDS was inversely correlated with the total prednisone dose given (r=-0.50, P=0.03). In 16 prepubertal children with serial height and serum protein measurements who were off steroids and maintained normal creatinine levels, mean individual albumin concentrations correlated with the change in height SDS per year (r=0.65, P=0.0006) and in boys with final height (r=0.73, P=0.03). In conclusion, growth in steroid-resistant NS depends on the preservation of renal function, the cumulative dose of steroids applied, and the severity of hypoproteinemia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10603130     DOI: 10.1007/s004670050709

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  7 in total

1.  The plasma permeability factor in nephrotic syndrome: indirect evidence in pediatric peritoneal dialysis.

Authors:  Marta Azocar; Lily Quiroz; Angela Delucchi; Hector Dinamarca; Marcos Emilfork; Francisco Cano
Journal:  Perit Dial Int       Date:  2012-04-02       Impact factor: 1.756

2.  Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome.

Authors:  Nynke Teeninga; Joana E Kist-van Holthe; Nienske van Rijswijk; Nienke I de Mos; Wim C J Hop; Jack F M Wetzels; Albert J van der Heijden; Jeroen Nauta
Journal:  J Am Soc Nephrol       Date:  2013-01       Impact factor: 10.121

3.  Growth in boys with idiopathic nephrotic syndrome on long-term cyclosporin and steroid treatment.

Authors:  Valérie Leroy; Véronique Baudouin; Corinne Alberti; Geneviève Guest; Patrick Niaudet; Chantal Loirat; Georges Deschenes; Paul Czernichow; Dominique Simon
Journal:  Pediatr Nephrol       Date:  2009-08-11       Impact factor: 3.714

4.  Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study.

Authors:  Djalila Mekahli; Aurelia Liutkus; Bruno Ranchin; Anchalee Yu; Lucie Bessenay; Eric Girardin; Rita Van Damme-Lombaerts; Jean-Bernard Palcoux; François Cachat; Marie-Pierre Lavocat; Guylhène Bourdat-Michel; François Nobili; Pierre Cochat
Journal:  Pediatr Nephrol       Date:  2009-03-12       Impact factor: 3.714

5.  Growth in steroid-responsive nephrotic syndrome: a study of 85 pediatric patients.

Authors:  Teresinha L Donatti; Vera H Koch; Maria D Fujimura; Yassuhiko Okay
Journal:  Pediatr Nephrol       Date:  2003-05-16       Impact factor: 3.714

6.  Long-term linear growth of children with severe steroid-responsive nephrotic syndrome.

Authors:  Francesco Emma; Antonella Sesto; Gianfranco Rizzoni
Journal:  Pediatr Nephrol       Date:  2003-06-13       Impact factor: 3.714

7.  The Effect of Long-term Steroid Therapy on Linear Growth of Nephrotic Children.

Authors:  Abbas Madani; Sham-Una Umar; Rambod Taghaodi; Niloofar Hajizadeh; Ali Rabbani; Hadi Z-Mehrjardi
Journal:  Iran J Pediatr       Date:  2011-03       Impact factor: 0.364

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.